DNA three-lens brief
Evidence-based stock research on DNA. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Moved -4.11% yesterday. · Currently unprofitable on a trailing basis — no P/E multiple available.
- Moved -4.11% yesterday.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Negative free cash flow last quarterly (-$77.93M).
- Earnings scheduled 2026-08-06.
DNA closed at $9.33 (-4.11%) as of 2026-07-10. Market cap: $609.48M. Price is above the 50-day MA and above the 200-day MA. Concerns: moved -4.11% yesterday.; currently unprofitable on a trailing basis — no P/E multiple available.. Last quarter: Revenue $19.47M, net income -$82.59M, free cash flow -$77.93M. Watching for: 2026-08-06 earnings release (26 days out).
Why three lenses on DNA, not one.
A single reasoning model has blind spots it doesn’t know about. We examine DNAacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/DNA" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath DNA brief"></iframe>